Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988283 · ClinicalTrials.gov registry record · Phase 1
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors
A Phase 1 study of Pediatric Recurrent Central Nervous System Tumors, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT03988283: Recruiting Phase 1 study of Pediatric Recurrent Central Nervous System Tumors, sponsored by Washington University School of Medicine.
NCT03988283 is a Phase 1 study of Pediatric Recurrent Central Nervous System Tumors that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03988283, a Phase 1 study of Pediatric Recurrent Central Nervous System Tumors, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with central nervous system tumors that have returned or have been resistant to treatment.
Conditions Studied
Interventions
- PROCEDURE Peripheral blood draw
- BIOLOGICAL Personalized neoantigen DNA vaccine
- DEVICE Papivax Biotech TDS-IM v2.0
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-10-02 |
| Est. Completion | 2031-02-28 |
| Phase | Phase 1 |
What NCT03988283 shows while recruiting
NCT03988283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Pediatric Recurrent Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which Peripheral blood draw is the first listed.
NCT03988283 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03988283 about?
NCT03988283 is a clinical study titled "Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors". The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with central nervous system tumors that have returned or have been resistant to treatment.
What is the current status of trial NCT03988283?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2024-10-02. Estimated completion is 2031-02-28.
What conditions does trial NCT03988283 study?
This clinical trial studies the following conditions: Pediatric Recurrent Central Nervous System Tumors.
What interventions are being tested in trial NCT03988283?
The interventions under investigation include: Peripheral blood draw (PROCEDURE), Personalized neoantigen DNA vaccine (BIOLOGICAL), Papivax Biotech TDS-IM v2.0 (DEVICE).
Who is sponsoring clinical trial NCT03988283?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03988283 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03988283's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI